[(2R,3S,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl] hydrogen sulfate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(2R,3S,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl] hydrogen sulfate
• 化学式: C₈H₁₅NO₉S
• 分子量: 301.27
• InChiKey: WHCJUIFHMJFEFZ-RTRLPJTCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  171
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT
  申请人：Inovio Pharmaceuticals, Inc.

  公开号：US20190284263A1

  公开（公告）日：2019-09-19

  Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.
• [EN] THE IN VIVO USE OF CHONDROITINASE AND/OR HYALURONIDASE TO ENHANCE DELIVERY OF AN AGENT<br/>[FR] UTILISATION IN VIVO DE CHONDROÏTINASE ET/OU D'HYALURONIDASE POUR AMÉLIORER L'ADMINISTRATION D'UN AGENT
  申请人：INOVIO PHARMACEUTICALS INC

  公开号：WO2017190147A1

  公开（公告）日：2017-11-02

  Disclosed herein are methods of delivering an agent to a subject. Further disclosed herein are methods of treating a disease or disorder in a subject. The methods may include administering to the subject a chondroitinase polypeptide or a polynucleotide encoding a chondroitinase polypeptide in an amount sufficient to degrade glycosaminoglycans, and administering to the subject the agent. The methods may further include administering a hyaluronidase polypeptide or a polynucleotide encoding a hyaluronidase.